Omnicell, Inc. (NASDAQ:OMCL) has been given a consensus rating of “Buy” by the twelve brokerages that are covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $79.89.
Several research firms recently weighed in on OMCL. TheStreet downgraded shares of Trinity Industries from a “b” rating to a “c” rating in a research report on Thursday, April 25th. Benchmark restated a “hold” rating on shares of Western Digital in a research report on Friday, April 26th. Zacks Investment Research upgraded shares of Triple-S Management from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a research report on Monday, April 29th. ValuEngine upgraded shares of Valmont Industries from a “sell” rating to a “hold” rating in a research report on Friday. Finally, Craig Hallum upgraded shares of PROS from a “hold” rating to a “buy” rating and upped their price target for the stock from $36.00 to $60.00 in a research report on Friday, April 26th.
In related news, EVP Scott Peter Seidelmann sold 1,750 shares of the company’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $81.55, for a total transaction of $142,712.50. Following the completion of the sale, the executive vice president now owns 28,083 shares of the company’s stock, valued at approximately $2,290,168.65. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Dan S. Johnston sold 8,210 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $81.16, for a total transaction of $666,323.60. Following the sale, the executive vice president now directly owns 36,504 shares of the company’s stock, valued at approximately $2,962,664.64. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 146,028 shares of company stock valued at $10,741,639. 2.77% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. LS Investment Advisors LLC grew its stake in shares of Omnicell by 5.6% in the 1st quarter. LS Investment Advisors LLC now owns 2,460 shares of the company’s stock valued at $199,000 after buying an additional 130 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in shares of Omnicell by 7.9% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,917 shares of the company’s stock valued at $236,000 after buying an additional 213 shares during the period. Oregon Public Employees Retirement Fund grew its stake in shares of Omnicell by 1.8% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 15,347 shares of the company’s stock valued at $1,241,000 after buying an additional 277 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of Omnicell by 125.0% in the 1st quarter. Nisa Investment Advisors LLC now owns 540 shares of the company’s stock valued at $44,000 after buying an additional 300 shares during the period. Finally, Parallel Advisors LLC purchased a new stake in shares of Omnicell in the 1st quarter valued at approximately $28,000. 97.30% of the stock is owned by institutional investors.
Shares of OMCL traded down $6.50 during mid-day trading on Tuesday, hitting $68.61. 1,827,283 shares of the company were exchanged, compared to its average volume of 469,662. Omnicell has a 1-year low of $52.20 and a 1-year high of $92.59. The company has a current ratio of 1.96, a quick ratio of 1.47 and a debt-to-equity ratio of 0.13. The firm’s 50 day simple moving average is $83.41. The stock has a market cap of $2.83 billion, a PE ratio of 44.84, a price-to-earnings-growth ratio of 2.22 and a beta of 1.13.
Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, April 25th. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.38. Omnicell had a net margin of 4.74% and a return on equity of 11.10%. The firm had revenue of $202.50 million during the quarter, compared to the consensus estimate of $199.72 million. During the same quarter in the prior year, the firm earned $0.29 EPS. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. On average, equities research analysts expect that Omnicell will post 2.06 EPS for the current year.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Featured Story: The risks of owning bonds
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.